Catalent und BrainStorm Cell Therapeutics geben Partnerschaft zur Herstellung von NurOwn®, einer auf mesenchymalen Stammzellen beruhenden Therapie, bekannt
October 23, 2020 11:25 ET
|
BrainStorm Cell Therapeutics Inc.; Catalent
SOMERSET, N.J. und NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), der weltweit führende Anbieter von modernen Verabreichungstechnologien, Entwicklungs- und Fertigungslösungen für...
Catalent et BrainStorm Cell Therapeutics annoncent un partenariat pour la conception de la plateforme de thérapie par cellules souches mésenchymateuses NurOwn®
October 23, 2020 11:25 ET
|
BrainStorm Cell Therapeutics Inc.; Catalent
SOMERSET, N.J.et NEW YORK, 23 oct. 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE : CTLT), le plus grand fournisseur mondial de solutions de fabrication, de développement et de technologies...
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
October 22, 2020 09:00 ET
|
BrainStorm Cell Therapeutics Inc.; Catalent
SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for...
BrainStorm to Present at Scientific Conferences in September
September 03, 2020 09:00 ET
|
BrainStorm Cell Therapeutics Inc.
Advanced Therapies & Expo 2020 on September 9 CIRM 2020 Grantee Meeting on September 14 Collaborations That Transform MS Webinar on September 24 NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) --...
BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs
September 02, 2020 08:30 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the...
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS
July 23, 2020 07:00 ET
|
BrainStorm Cell Therapeutics Inc.
Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model BrainStorm will...
BrainStorm Granted SME Status by the European Medicines Agency
June 15, 2020 09:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it...
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
May 07, 2020 06:30 ET
|
BrainStorm Cell Therapeutics Inc.
Conference Call and Webcast Today at 8:30 a.m. Eastern Time ALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data Readout NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell...
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
May 07, 2020 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative...
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
May 04, 2020 03:30 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that...